BioSpace News Archive

Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, Dr. David Giljohann, will give a company presentation on Monday, April 8, 2019 at 11:50 am GMT at the H.C. Wainwright Global Life Sciences Conference.

PrinterPrezz Inc. announced that Greg Morris, a pioneer in additive manufacturing and formally of GE Aviation, will join its advisory board.

CMO to Drive Physician Leadership & Clinical Innovation to Improve the Continuum of Cancer Care in Every Community